CSV December 7, 2017 through December 7, 2019 See all Errata for USP–NF How to use
×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
  - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
  - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
  - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular Weight Impurities*	*USP42–NF37*	857	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
BACILLUS COAGULANS CAPSULES	ASSAY/*Enumeration*	*USP42–NF37*	4749	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
BACILLUS COAGULANS	ASSAY/*Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
BACILLUS COAGULANS	ASSAY/*Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Sample preparation* and *Analysis*: Change peptone water to: *Peptone diluent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<561> ARTICLES OF BOTANICAL ORIGIN	TEST FOR AFLATOXINS/ *Method I*	*USP42–NF37*	6701	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Aflatoxin standard solution*: Change ? = molecular absorptivity to: ? = molar absorptivity AND in paragraph 2 of *Aflatoxin standard solution*: Change transfer an accurate volume of each aflatoxin standard stock solution to: transfer an accurate volume of each aflatoxin stock solution
REAGENTS AND REFERENCE TABLES	SOLUTIONS/*0.01 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
REAGENTS AND REFERENCE TABLES	SOLUTIONS/*0.02 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	10. ALLIGATION ALTERNATE AND ALGEBRA METHODS FOR COMBINING MULTIPLE STRENGTHS OF THE SAME ACTIVE PHARMACEUTICAL INGREDIENT	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In *10.2 Algebra Method/10.2.1 Calculating by using the algebra method/Examples—Algebra method*: In example *2*, in equations 1, 2, 3, and 4 in all instances: Change C_s to: Q_s AND In example 2, in equation 5: Change C_w to: Q_w
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1/ Instrumental conditions*	*USP42–NF37*	4409	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Cell*: Change 5 cm to: 5 mm
THALIDOMIDE	*Assay*	*USP42–NF37*	4281	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Chromatographic system*: Change and the relative standard deviation for replicate injections is not more than 1.0%. to: and the relative standard deviation for the response ratio of thalidomide to phenacetin is not more than 1.0%.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM BICARBONATE COMPOUNDED INJECTION	ASSAY/*Procedure for Sodium Bicarbonate*	*USP42–NF37*	4023	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change Result = $[(V_S ? V_B) \times N_A \times F] \times 100$ to: Result = $[(V_S ? V_B) \times N_A \times F \times 100]/W$ AND Change *F* = equivalency factor, 84.01 mg/mL to: *F* = equivalency factor, 84.01 mg/mEq *W* = sample weight (mg)
PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>*	*Revision Bulletin (Official March 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In the *Figure 1* caption: Change (see *Drug Release <724>*, *Figure 4c*) to: (see *Drug Release <724>*, *Figure 5c*)
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 4 of Column 1 of *Table 5*: Change Morphine related compound B[b] to: Morphine related compound B (anhydrous)[b]
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Morphine Related Compound B RS: Change 2,2'-Bimorphine. $C_{34}H_{36}N_2O_6$?568.66 to: 2,2'-Bimorphine trihydrate. $C_{34}H_{36}N_2O_6 ? 3H_2O$?622.72
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2518	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).]? (USP 1-May-2019) to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 3 of *Table 3*: Change Levalbuterol?—? —?— to: Levalbuterol?1.0?—?—
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Limit of S-Albuterol*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Mobile phase*: Change ?*Acetonitrile*, *methanol*, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.? (USP 1-May-2019) to: Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVALBUTEROL INHALATION SOLUTION	ADDITIONAL REQUIREMENTS/ *USP Reference Standards <11>*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde; Also known as 5-[2-{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol. $C_{13}H_{19}NO_3$ 237.29 [NOTE: This Reference Standard is available as the benzesulfonic acid salt.] to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
INOSITOL	IMPURITIES/*Limit of Lead*	*USP42–NF37*	5776	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Standard lead solution*: Delete A comparison solution prepared on the basis of 100 µL of the *Standard lead solution* per g of substance being tested contains the equivalent of 1 part of lead per million parts of substance being tested.
IMIPRAMINE PAMOATE CAPSULES	ASSAY/*Procedure*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A* and *Solution B* and *Diluent*: Change *Chromatographic acetonitrile* to: Acetonitrile In *Solution A*: Change *Chromatographic acetonitrile* to: Acetonitrile AND In *Solution B*: Change *chromatographic acetonitrile* to: acetonitrile
IMIPRAMINE PAMOATE CAPSULES	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	
HYPROMELLOSE PHTHALATE	IMPURITIES/*Chloride and Sulfate <221>, Chloride*	*Harmonization (Official May 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change ?Add 1 mL of silver nitrate TS to the *Standard solution* and then add a 50-mL portion of the *Sample solution*. Mix and allow to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.?(NF 1-May-2019) to: Add 1 mL of silver nitrate TS to the *Standard solution*. Add 1 mL of silver nitrate TS to a 50-mL portion of the *Sample solution*. After mixing, allow each solution to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.
FELODIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP42–NF37*	1787	26-Apr-2019	1-May-2019	*NA*	*NA*	In the second variable definition list in *Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point, *i* to: V_S = volume of the *Sample solution* withdrawn at each time point, *i* (mL)
CLONIDINE TRANSDERMAL SYSTEM	PERFORMANCE TESTS/ *Drug Release <724>/Test 1*	*USP42–NF37*	1084	26-Apr-2019	1-May-2019	*NA*	*NA*	*Apparatus 7*: Change (see *Figure 4a*). to: (see *Figure 5a*).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/*Procedure*/ *Chromatographic system*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* ?(90:10)? (ERR 1-Mar-2019) for about 30 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 2 of Column 3 of *Table 4*: Change 0.014?/0.028?2S *(USP41)* to: 0.014 AND In Row 3 of Column 3 of *Table 4*: Change 0.014 to: 0.014/0.028 AND In *Chromatographic system*/*Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) for NLT 20 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/ *USP Reference Standards <11>*	*USP42–NF37*	410	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Atorvastatin Related Compound A RS: Change Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2-isopropyl-4,5-diphenyl-3-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.
<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	19. MEAN KINETIC TEMPERATURE/*19.2 MKT Equation*	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In the variable definition list: Change T_n = value for the total number of storage temperatures recorded during the observation period temperature recorded during the nth time period, e.g., *n*th week to: T_n = value for the temperature recorded during the *n*th time period, e.g., *n*th week
<855> NEPHELOMETRY AND TURBIDIMETRY	4. INSTRUMENTATION	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 2: Change silicone diodes to: silicon diodes
<855> NEPHELOMETRY AND TURBIDIMETRY	5. FORMAZIN TURBIDITY STANDARDS	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 1: Change *IUPAC Compendium of Chemical Technology*, to: *IUPAC Compendium of Chemical Terminology*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6104	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Ferric Nitrate*: Change [10421-48-4]. to: [7782-61-8].
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6079	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Beef Extract*/*Microbial Content*: Change MT to: NMT
SCOPOLAMINE HYDROBROMIDE	IDENTIFICATION/*B.*	*First Supplement to USP41–NF36*	8420	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample solution*: Change 50 mg/mL of alcohol to: 50 mg/mL in water
RUTIN	CHEMICAL INFORMATION	*USP41–NF36*	4841	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*-chromen-4-one-3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside [250249-75-3]. to: 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*-chromen-4-one-3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside trihydrate [250249-75-3].
PREDNISOLONE SODIUM PHOSPHATE	*Related compounds*	*USP41–NF36*	3416	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Table 1*: Add Prednisolone sodium phosphate 1.00 — —
METAXALONE	IDENTIFICATION/*B.*	*USP41–NF36*	2611	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change The retention time of the major peak of the *Sample solution* corresponds to that of the *Sample solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
MERCAPTOPURINE	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2587	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change *Sample solution*: 0.12 mg/mL of Mercaptopurine in *Solution A*. [NOTE—Inject the *Sample solution* within 1 h of preparation.] to: *Sample stock solution*: 0.5 mg/mL of mercaptopurine in a mixture of methanol and *Solution A* (1:9) prepared as follows. Transfer a suitable quantity of Mercaptopurine to an appropriate volumetric flask, add methanol equivalent to 10% of the final volume, and shake to dissolve. Dilute with *Solution A* to volume. *Sample solution*: 0.12 mg/mL of mercaptopurine in *Solution A* from the *Sample stock solution*. [NOTE—Inject the *Sample solution* within 1 h of preparation.]
ISOPHANE INSULIN HUMAN SUSPENSION	ASSAY/*Procedure*	*Interim Revision Announcement (Official January 01, 2019)*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Standard solution*: Change USP Insulin Beef RS to: USP Insulin Human RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BUMETANIDE TABLETS	ASSAY/*Procedure*	*Second Supplement to USP41–NF36*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample solution*: Change Nominally 0.05 mg/mL of bumetanide prepared as follows. to: Nominally 125 µg/mL of bumetanide prepared as follows.
PRAZOSIN HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION	ASSAY/*Procedure*	*Second Supplement to USP41–NF36*	8945	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Mobile phase*: Change tetramethylammonium hydrochloride to: tetramethylammonium hydroxide
OXANDROLONE	*Related compounds*	*USP41–NF36*	3072	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In footnote 4 of the second table: Change Methyl-(1,17?-dihydroxy-17?-methyl-1,3-seco-2-nor-5?-androstane-3-oate. to: Methyl 1,17?-dihydroxy-17?-methyl-1,3-seco-2-nor-5?-androstan-3-oate.
METHYLDOPA	SPECIFIC TESTS/*Optical Rotation <781S>*	*USP41–NF36*	2666	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Sample solution*: Change aluminum chloride to: aluminum chloride hexahydrate
MESNA TABLETS	ADDITIONAL REQUIREMENTS/ *USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8906	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98
MESNA	ADDITIONAL REQUIREMENTS/ *USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8904	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUDROCORTISONE ACETATE TABLETS	IMPURITIES/*Organic Impurities*/*Table 1*	*Second Supplement to USP41–NF36*	8843	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In footnote a: Change 9-Fluoro-11?,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate. to: 9-Fluoro-11?,17,21-trihydroxypregn-4-ene-3,20-dione.
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*USP41–NF36*	1358	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Buffer*: Change 0.5 g/L of citric acid and 0.4 g/L of dibasic sodium phosphate in water to: 0.5 g/L of anhydrous citric acid and 0.4 g/L of anhydrous dibasic sodium phosphate in water
DEXMEDETOMIDINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP41–NF36*	Online	22-Feb-2019	1-Mar-2019	*NA*	*NA*	This erratum applies to the *USP-NF* ONLINE platform only. See https://www.uspnf.com/sites/default/files/usp_pdf/EN/february_2019_errata_image1.pdf for correction
CARBINOXAMINE MALEATE TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8788	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Standard stock solution*: Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the *Standard solution*: Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the *Analysis*: Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBINOXAMINE MALEATE	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8786	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Standard stock solution*: Change (equivalent to 0.05 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.05 mg/mL of carbinoxamine) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the *Standard solution*: Change (equivalent to 0.001 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.001 mg/mL of carbinoxamine) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the *Analysis*: Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base)
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/*Procedure*/*Chromatographic system*	*Second Supplement to USP41–NF36*	8781	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Column*: Change [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) to: [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (90:10)

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Current page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Next page Next ›
- Last page Last »